Results 1 to 10 of about 621,365 (219)
Chinese Journal of Lung Cancer, 2023 With the development of precision diagnosis and treatment for non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, as a rare subset of EGFR mutaions, have gradually attracted attention ...
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
doaj +1 more source
Expert Consensus on Prevention and Treatment of COVID-19 Infection in Patients with Lung Cancer
Chinese Journal of Lung Cancer, 2023 Corona virus disease 2019 (COVID-19) infection has become a major public health issue affecting human health. The main goal of epidemic prevention and control at the current stage in China is to “protect people’s health and prevent severe cases ...
Non-small Cell Lung Cancer Expert Committee of Chinese Society of Clinical Oncology +1 more
doaj +1 more source
Drugs in Context, 2022 The therapeutic approach to patients affected by advanced non-small-cell lung cancer (NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new treatment strategies, such as immunotherapy and tyrosine kinase inhibitors, has ...
Andrea De Giglio +5 more
doaj +1 more source
Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
Chinese Journal of Lung Cancer, 2021 Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T ...
Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy +1 more
doaj +1 more source
MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties
Frontiers in Oncology, 2020 MicroRNA-24 (miR-24) has been widely studied in a variety of human cancers, which plays different roles in specific type of cancers. In the present review, we summarized the recent surveys regarding the role of miR-24 in different human cancers.
Sumei Wang +18 more
doaj +1 more source
Non-small-cell lung cancer: how to manage RET-positive disease
Drugs in Context, 2022 Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling ...
Elisa Andrini +6 more
doaj +1 more source
Non-small-cell lung cancer: how to manage EGFR-mutated disease
Drugs in Context, 2022 The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshaped ...
Federica Pecci +6 more
doaj +1 more source
Non‐small cell lung cancer in China
Cancer Communications, 2022 In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer
Peixin Chen +3 more
doaj +1 more source
Non-small-cell lung cancer: how to manage BRAF-mutated disease
Drugs in Context, 2023 BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes
Giorgia Guaitoli +5 more
doaj +1 more source
Chinese Journal of Lung CancerThe standard clinical practice of managing the non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations was elaborated in Chinese expert consensus on non‑small cell lung cancer with EGFR exon ...
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee
doaj +1 more source